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ABSTRACT 
A simple, Accurate, precise method was developed for the simultaneous 
estimation of the esomeprazole and levosulpiride in Tablet dosage form. 
Chromatogram was run through ODS (150mm 4.6mm, 5µ). Mobile phase containing 
Buffer and Acetonitrie in the ratio of 32;68A was pumped through column at a flow 
rate of 1ml/min. Buffer used in this method was 0.01N KH2PO4 pH 5.4 buffer. 
Temperature was maintained at 30°C. Optimized wavelength for Esomeprazole and 
Levosulpiride was 290nm. Retention time of Esomeprazole and Levosulpiride were 
found to be 2.2min and 4.0min. %RSD of the Esomeprazole and Levosulpiride were 
and found to be 0.97 and 0.50 respectively. %Recover was Obtained as 100.08% and 
101.16% for Esomeprazole and Levosulpiride respectively. LOD, LOQ values are 
obtained from regression equations of Esomeprazole and Levosulpiride were 
0.10ppm, 0.34ppm and 1.04ppm, 0.29ppm respectively. Regression equation of 
Esomeprazole is y = 10568.x + 307.3, and of Levosulpiride is y = 11649.x + 1207. 
Key Words: Esomeprazole, Levosulpiride, RP-HPLC. 
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1. INTRODUCTION 
 A drug includes all medicines intended for internal or external use for or in the 
diagnosis, treatment, mitigation or prevention of disease or disorder in human beings 
or animals, and manufactured exclusively in accordance with the formulae mentioned 
in authoritative books. (1) 
Pharmaceutical analysis is a branch of chemistry involving a process of 
identification, determination, quantification, purification and separation of 
components in a mixture or determination of chemical structure of compounds. There 
are two main types of analysis – Qualitative and Quantitative analysis. 
 Qualitative analysis is performed to establish composition of a substance. It is 
done to determine the presence of a compound or substance in a given sample or not. 
The various qualitative tests are detection of evolved gas, limit tests, color change 
reactions, determination of melting point and boiling point, mass spectroscopy, 
determination of nuclear half life etc. 
 Quantitative analysis techniques are mainly used to determine the amount or 
concentration of analyte in a sample and expressed as a numerical value in 
appropriate units. These techniques are based on suitable chemical reaction and either 
measuring the amount of reagent added to complete the reaction or measuring the 
amount of reaction product obtained the characteristic movement of a substance 
through a defined medium under controlled conditions, electrical measurement or 
measurement of spectroscopic properties of the compound.(2) 
  
Chapter 1   Introduction 
Dept. of Pharmaceutical Analysis 10 J.K.K.Nattraja College of Pharmacy 
1.1 High Performance Liquid Chromatography 
Chromatography is the method of separation that finds applications in all 
branches of science. It was first invented by Russian Botanist Mikhail Twsett. This 
technique was used to separate various plant pigments like chlorophylls and 
xanthophylls by passing solutions of these compounds through a glass column packed 
with finely divided calcium carbonate. The separated species appear as colored bands 
on the column hence the name of the process (Greek chroma meaning “color” and 
graphing meaning “writing”)(3) 
 Chromatography is defined as a non- destructive procedure for resolving 
multi-component mixture of trace, minor, or major constituents into its individual 
fractions. In chromatography, the sample is dissolved in the mobile phase which may 
be a gas, liquid, or a supercritical fluid. The principle involved in HPLC is that when 
a mixture containing different compounds is introduced into the mobile phase and 
allowed to flow over a stationary phase, the individual compounds travel at different 
speeds and get separated based on the relative affinities to the stationary phase and 
the mobile phase. The compounds are separated based on the polarity of the 
stationary phase and the mobile phase. 
 Chromatography is of various types based on the physical state of the 
stationary and the mobile phase: 
1. Solid - Liquid type: The stationary phase is a solid and the mobile phase is a liquid. 
Ex: Thin layer chromatography, High performance liquid chromatography (HPLC). 
2. Liquid - Liquid type: The stationary phase is a liquid and the mobile phase is 
also a liquid. Ex: Paper Chromatography, HPLC. 
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3. Liquid - Gas Type: The stationary phase is a liquid and the mobile phase is a 
gas. Ex: Gas chromatography. 
High Performance Liquid Chromatography is the most widely used of all the 
analytical separation techniques. The reasons for its popularity are its sensitivity, 
ready adaptability to quantitative determination, suitability for non- volatile and 
thermally fragile species, wide applicability to variety of substances such as amino 
acids, carbohydrates, nucleic acids, proteins, hydrocarbons, terpenoids, pesticides, 
steroids, metal-organic species and inorganic species. As high pressures (around 3000 
psi) are used for the separation of the analytes down the column, it is often termed as 
High Pressure Liquid Chromatography.(4 
1.2 Types Of HPLC (5) 
HPLC is classified into various types  
a) Based on polarity of stationary and mobile phase 
• Normal Phase Chromatography 
• Reverse Phase Chromatography 
b) Based on the principle of separation  
• Adsorption Chromatography 
• Partition Chromatography 
• Ion Pair Chromatography 
• Size Exclusion Chromatography 
• Chiral Phase Chromatography 
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C) Based on elution technique 
• Isocratic Elution 
• Gradient Elution 
D) Based on scale of operation 
• Analytical HPLC 
• Preparative HPLC  
a) Based on the polarity of the stationary phase and the mobile phase, it is of two types: 
Normal Phase (NP) HPLC 
 In this type, the stationary phase is polar and the mobile phase is non-polar, 
polar compounds are retained for a longer periods because of more affinity towards 
the stationary phase, hence non-polar compounds travel faster and are eluted first. 
Reverse Phase (RP) HPLC 
In this type, the stationary phase is non-polar and the mobile phase is polar, 
non-polar compounds are retained for longer periods as they have more affinity towards 
the stationary phase. Hence, polar compounds travel faster and are eluted first.  
Table 1.1 Types of HPLC Based on Polarity of Stationary Phase and Mobile Phase. 
 
b) Based on the principle of separation, chromatography is divided into various 
types, 
Types Normal Phase Reverse Phase 
Stationary phase Polar Non polar 
Mobile phase Non polar Polar 
Compound eluted first Non polar Polar 
Compound eluted last Polar Non polar 
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Adsorption chromatography 
 It is one of the oldest types of chromatography. The principle involved is 
adsorption. Adsorption is a surface phenomenon in which the separation mechanism 
depends on the difference in the polarity of various drug molecules. The more polar a 
molecule, the more strongly it will be adsorbed by a polar stationary phase. Similarly 
the more non-polar a molecule, the more strongly it will be adsorbed by a non-polar 
stationary phase.(6) 
During a surface adsorption chromatography process, a competition for 
stationary phase adsorption sites exists between the materials to be separated and the 
mobile phase. In a mixture, molecules of low polarity spend proportionally more time 
in the mobile phase than those molecules that are highly polar, which are retained for 
a longer period of time. Therefore the components of a mixture are eluted in order of 
increasing polarity. (7)  
Partition Chromatography 
The principle involved is partition in which the solute molecules distribute 
themselves between the mobile and the stationary phases. In partition 
chromatography the stationary phase is a non-volatile liquid which is held as a thin 
layer (or film) on the surface of an inert solid. The mixture to be separated is carried 
by a gas or a liquid as the mobile phase. With the use of liquid as mobile phases, there 
is a tendency for the stationary liquid phase to be removed or dissolved. Therefore, 
the stationary liquid phase has to be chemically bonded to the solid bonding support 
such as silica gel, cellulose powder, or kieselguhr (hydrated silica). The solute 
molecules in the mobile phase move through the system at rates determined by their 
relative solubility’s in the stationary and mobile phases.(8) 
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Ion Exchange Chromatography 
Ion Exchange Chromatography is based on the reversible interaction between 
a charged protein and an oppositely charged chromatography medium. Biomolecules 
such as proteins, peptides, nucleic acids with even small differences in net surface 
charge can be separated, and very high resolution is obtained by choosing the optimal 
ion exchange and separation conditions. The net surface charge of a protein varies 
according to the surrounding pH. Typically, when the pH is above its isoelectric 
point, a protein will bind to a positively charged anion exchanger. Below its 
isoelectric point, a protein will bind to a negatively charged cat ion exchangers.(9)     
 Anion and cation exchangers are classified as strong or weak, depending on 
how much the ionization state of the functional groups vary with pH. A strong ion 
exchange has the same charge density on its surface over a broad pH range, whereas 
the charge density of a weak ion exchanger changes with pH. The selectivity and the 
capacity of weak ion exchangers are different at different pH values.(10) 
Size Exclusion Chromatography  
 This process is also known as Gel Permeation Chromatography. In this 
method the mixture of compounds with various molecular sizes are separated 
according to size or molecular weight. The stationary phase consists of a porous 
cross-linked polymeric gel. The pores of the gel normally small and exclude the 
larger solute molecules, but allows smaller molecules to enter the gel, causing them to 
flow through a larger volume. This causes the larger molecules to pass through the 
column at a faster rate than the smaller ones. The components of a mixture therefore 
elute in order of decreasing size or molecular weight.(11) 
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 Size Exclusion Chromatography is used extensively in the biochemical 
industry to remove small molecules and inorganic salts from valuable higher 
molecular weight products such as peptides, proteins and enzymes. 
Chiral Phase Chromatography  
 In this type of chromatography, optical isomers are separated using chiral 
stationary phases. Two approaches for chiral separation are available, indirect, which 
utilizes derivatizing agents, and direct, which uses chiral stationary phases or chiral 
mobile phase additives.  In the indirect method, a racemic mixture is made to react 
with a chiral reagent to form a pair of diastereomers and then chromatographed using 
a chiral column. Because diastereomers possess different physiochemical properties, 
they can be separated in a chiral environment.  
 Direct separation of enantiomers on and a chiral column using a chiral mobile 
phase additive is applied only in HPLC.  In this method, enantiomeric separation is 
accomplished by the formation of a pair of transient diastereomeric complexes 
between racemic analyte and the chiral mobile phase additive.  Chiral discrimination 
is due to differences in the stabilities of the diastereomeric complexes, salvation in the 
mobile phase, and/or binding of the complexes to the solid support.(12)                         
c) Based on elution technique, chromatographic methods are of two types, 
Isocratic Elution 
 In this technique, the composition of the mobile phase is maintained as constant 
throughout the process of separation. All the compounds in the sample are eluted in a 
reasonable amount of time, by changing the ratio of polar to non-polar compounds in 
the mobile phase during the sample run while maintaining peak resolution.  
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Gradient Elution 
 A steady change of the mobile phase composition during the chromatographic 
run is called gradient elution. This is widely used technique when a sample contains 
components of a wide range of polarities. For a reverse phase gradient, the solvent 
starts out relatively polar and slowly becomes more non-polar. The gradient elution 
offers the most complete separation of the peaks, without taking much time. A sample 
containing compounds of a wide range of polarities can be separated by a gradient 
elution in a shorter time period without a loss of resolution in the earlier peaks or 
excessive broadening of later peaks.(13) 
 Gradient elution also increases quasi-efficiency of the column. In the isocratic 
elution, the longer a component is retained, the wider its peak. In gradient elution, the 
tail of the peak is always under the influence of the stronger mobile phase when 
compared to the peak front. Thus, molecules on the tail of the chromatographic peak 
will move faster. This will tend to compress zone and narrow the resultant peak. (14) 
d) Based on the scale of operation, chromatography is of two types, 
Analytical HPLC 
 In Analytical HPLC, quantitative and qualitative determination of a compound 
is done. It is the most widely used technique. In this method, the sample amount 
applied to the column is typically in the µg range or lower quantities. The mass ratio 
of compound to the stationary phase on the column is less than 1: 100000. Under 
these conditions good separations with sharp and symmetrical peaks are achieved. 
Recovery of samples is not possible as small quantities of the sample are used. (15) 
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Preparative HPLC 
 In Preparative HPLC, isolation and purification of a product is done. It is an 
expensive technique, when compared to the traditional purification techniques like 
distillation, crystallization or extraction. 
 Preparative HPLC is used for the isolation and purification of valuable 
products in the chemical and pharmaceutical industry as well as in biotechnology and 
biochemistry. It starts in the µg range for isolation of enzymes in biotechnology 
(micro purification). For identification and structure elucidation of unknown 
compounds in synthesis or natural product chemistry it is necessary to obtain pure 
compounds in amounts ranging from one to a few milligrams. Larger amounts, in 
gram quantity, are necessary for standards, reference compounds and compounds for 
toxicological and pharmacological testing. Industrial scale or production scale 
preparative HPLC, that is, kg quantities of compound, is often done nowadays for 
valuable pharmaceutical products.            
1.3 Instrumentation of HPLC 
The main components of HPLC are as given below and are schematicall 
represented in Fig 1.1 
1. Solvent Reservoir 
2. Solvent Delivery System (Pump)  
3. Injection Port/ Auto sampler 
4. Column 
5. Detector 
6. Data Acquisition system 
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        Fig. 1.1 Schematic diagram of instrumentation of HPLC
1.3.1    Solvent Reservoir
 Solvent Reservoirs are used to store mobile phase. Scott Duran bottles are 
commonly used as solvent reservoirs. The 
material such as glass and must be smooth so as to avoid growth of microorganisms 
on its walls. It may be transparent or can be amber colored. A graduated bottle gives a 
rough estimate of mobile
above HPLC system (at higher level) in a tray. They should never be kept directly 
above the system as any spillage of solvent on the system may damage electronic 
parts of HPLC. 
1.3.2 Solvent Delivery System (Pump)
 Pumps are an important component of the HPLC system. It delivers a constant 
flow of mobile phase such that the separation of components of mixture takes place in 
a reasonable time. There are different types of pumps: 
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solvent reservoir must be made of inert 
-phase volume in the bottle. Solvent reservoirs are placed 
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(16)
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a) Reciprocating Pumps 
b) Displacement Pumps 
c) Pneumatic Pumps 
 In reciprocating pumps, a motor driven reciprocating piston controls the flow 
of mobile phase with the help of two ball check valves that opens and closes with the 
piston movement. The flow is thus not continuous and as damping of flow is 
necessary, it is accomplished using pulse dampers which are a long coiled capillary 
tube. Reciprocating pumps are most widely used in HPLC systems.  
 Displacement pumps, also known as syringe pump is  composed of a one 
directional motor driven plunger that pushes the mobile phase present in a syringe 
like chamber. The volume of displacement pumps is limited. A constant flow rate is 
usually obtained with syringe like pumps.  
  Pneumatic pumps are the simplest where the mobile phase is pushed out of 
the mobile phase container by the pressure of a pressurized gas. The flow is 
dependent on the back pressure of the column and usually the flow is limited to 
pressures below 2000 psi. (17) 
1.3.3    Injection Port or Auto sampler (18) 
The Sample Injector enables small liquid samples to be injected into the 
HPLC system without the sample passing through the pump. The function of the 
injector is to place an accurate volume of the sample into the high-pressure flow of 
the mobile phase so that the sample enters the column as a homogeneous, low-volume 
plug. It is of two types; manual injector or an auto injector. Injection is done through 
specially designed 6-port rotary injection valve or a Rheodyne valve as shown in Fig 
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1.2. The sample is introduced at atmospheric pressure by a syringe into a constant 
volume loop. In the LOAD position the loop is not in the path of the mobile phase. 
By rotating to the INJECT position the sample in the loop i
phase stream into the column. It is important to allow some sample to flow into waste 
from loop so as to ensure there are no air bubbles in the loop and
sample is completely washed out to prevent previous sample effect
loading can be varied by part filling of the loop or by changing the loop volume.
Automatic injection improves laboratory productivity and eliminates personal 
errors. Present day advanced HPLC systems are equipped with an auto injector along 
with an auto sampler. The software programs help filling of the loop and delivery of 
the sample to the column. The computer controls the sequence of samples for 
injection from vials kept in numbered positions of the auto sampler. It is important to 
adopt precautions to ensure consistency of results. 
Fig. 1.2
1.3.4    HPLC Column 
 The HPLC column is referred to as the heart of the process. The stationary 
phase of the column is used in separating the individual fractions of a sample mixture 
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s moved by the mobile 
(19) 
   Flow Path of a Manual Injector. (20) 
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s. The sample 
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by using various physical and chemical parameters. Columns for analytical HPLC are 
of various sizes ranging from 10 - 25 mm in length and 2.6 – 4.6 mm internal 
diameter (i.d). Columns for preparative HPLC are in size range of 50 – 250 mm long 
and i.d greater than 4.6 mm. The columns are generally constructed of stainless steel 
SS-316 grade to cope with high back pressure (caused by the small particles of the 
stationary phase) and are glass lined to prevent metal catalysis of solvent- solute 
reactions at high column pressures (due to force of pumping of the mobile phase 
through the columns). Columns made of glass are used for the separation of 
Biomolecules and columns made of PEEK polymer are biocompatible and chemically 
inert to most solvents. (21) 
 
Fig No. 1.3 HPLC Column 
Stationary phase 
 Separation of pharmaceuticals is usually achieved by partition of compounds 
in the test solution between the mobile and the stationary phases. HPLC systems 
consisting of polar stationary phases and non-polar mobile phases are described as 
normal-phase chromatography; those with non-polar stationary phases and polar 
mobile phases are called reversed-phase chromatography. 
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There are many types of stationary phases used in HPLC including: 
- Unmodified silica, alumina, or porous graphite, used in normal-phase 
chromatography, where separation is based on differences in adsorption; 
- A variety of chemically modified supports prepared from polymers, silica, or porous 
graphite, used in reverse-phase HPLC, where separation is based principally on 
partition of the molecules between the mobile phase and the stationary phase; 
- Resins or polymers with acid or basic groups, used in ion-exchange 
chromatography, where separation is based on competition between the ions to be 
separated and those in the mobile phase; 
- Porous silica or polymers, used in size-exclusion chromatography, where separation 
is based on the relative molecular mass of the molecules. 
 Most separations are based on partition mechanisms using chemically 
modified silica as the stationary phase and polar solvents as the mobile phase 
(reverse-phase HPLC). The surface of the support, e.g. the silanol groups of silica, is 
reacted with various silane reagents to produce covalently bonded silyl derivatives 
covering a varying number of active sites on the surface of the support. The nature of 
the bonded phase is an important parameter for determining the separation properties 
of the chromatographic system. 
 For the separation of enantiomers, special chemically modified stationary 
phases (chiral chromatography) are available, e.g. cyclodextrins, albumins, etc. 
 Generally, silica-based reverse-phase columns are generally considered to be 
stable in mobile phases with an apparent pH in the range 2.0 - 8.0, but the column 
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manufacturer's instructions should be consulted before using the column. Columns 
containing particles of polymeric materials such as styrene divinyl benzene 
copolymer are stable over a wider pH range. 
For analytical separations the particle size of the most commonly used 
stationary phases varies between 3 µm and 10 µm. The particles may be spherical or 
irregular, of different porosities and specific surface area. In the case of reversed-
phase, the extent of bonding of the stationary phase is expressed as the carbon-
loading. Furthermore, stationary phases may be "end-capped", i.e. the number of 
residual silanol groups is reduced by methylation. These parameters contribute to the 
chromatographic behavior of a particular stationary phase. Tailing of peaks, 
particularly for basic substances, can occur when residual silanol groups are present.  
1.3.5    Detector (22) 
 A detector in the HPLC system measures the compounds after their separation 
from the column. The detector selected should be capable of responding to changes in 
the concentration of all the components in the sample with adequate sensitivity even 
to measure trace amounts. Basically there are two types of detectors: bulk property 
and solute property detectors. The bulk property detectors, function on some bulk 
property of the eluent such as refractive index (RI) and is not suitable for gradient 
elution and are usually less sensitive than solute property detectors. Solute property 
detectors perform by measuring a physical or chemical property that is specific to the 
solute. Detectors should have high linear dynamic range and should give faster 
response. The various detectors used and their applications are given in Table 1.2. 
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Table 1.2 Commonly used detectors and their application. (23) 
Detector Analyte detected 
Solvent 
requirements Uses 
UV-Visible 
Any 
compounds 
with 
chromophore 
Non UV 
absorbing 
solvents 
Wavelength at which maximum 
absorption occurs can be selected. 
Has a high degree of selectivity and 
is useful for many applications. 
Photo diode 
array (PDA) 
detector 
Any 
compound 
with 
chromophore 
Non UV 
absorbing 
solvents 
Detects an entire spectrum 
simultaneously. Useful for analysis 
of related substances and 
impurities. 
Fluorescence Fluorescent 
compounds 
Non UV 
absorbing 
solvents 
Highly selective and sensitive. 
Wavelength at which fluorescence 
occurs is selected. Often used to 
analyze derivatized samples after 
treatment with DANSYL chloride 
to form fluorescent compounds. 
Refractive 
index (RI) 
Compound 
with a 
different RI to 
that of the 
mobile phase 
Cannot run 
mobile phase 
gradients 
Virtually it is a universal detector 
but has limited sensitivity. Used for 
the detection of sugars. 
Conduct-ivity 
Charged or 
polar 
compounds 
Mobile phase 
must be 
conducting 
Excellent detector for ion exchange 
methods. 
Electro-
chemical 
 
Readily 
oxidized or 
reduced 
compounds 
Mobile phase 
must be 
conducting 
Very sensitive and selective. Used 
for detection of Biological 
compounds. 
Evaporative 
light scattering 
detector 
(ELSD) 
All 
compounds 
are detected 
virtually 
Volatile 
solvents and 
volatile buffers 
must be used. 
Universal detector, Highly sensitive 
but not selective. But can be use for 
gradient analysis. Used for the 
detection of lipids, sugar and high 
molecular weight analytes. 
Optical 
rotation 
detector 
Optically 
active 
compounds 
Mobile phase 
should be an 
asymmetric 
environment 
Detects R and L type of isomers 
 
Chapter 1   Introduction 
Dept. of Pharmaceutical Analysis 25 J.K.K.Nattraja College of Pharmacy 
1.3.6    Data Collection devices 
 Signals from the detector may be collected on chart recorders or electronic 
integrators that vary in complexity and in their ability to process, store and reprocess 
chromatographic data. The data storage capacity of these devices is usually limited. 
 Modern data stations are computer based and have a large storage capacity to 
collect process and store data for possible subsequent reprocessing. Analytical reports 
can often be customized to the needs of the analyst. 
 Integration of peak areas and the setting of threshold levels are not normally 
problematic in an assay since the peak of the substance to be analyzed should be free 
of interference. However, in a test for impurities, the selection of the peak area 
integrator parameters becomes very important, particularly when baseline separations 
are not always attainable. If baseline separations cannot be obtained, valley-to-valley 
integration should be employed. 
1.4  METHOD DEVELOPMENT AND VALIDATION  
Introduction to Method Development 
 The number of drugs introduced into the market is increasing every year. 
These drugs may be either new entities or partial structural modification of the 
existing one. Often a time lag exists from the date of introduction of a drug into the 
market to the date of its inclusion in pharmacopoeias. This happens because of the 
possible uncertainties in the continuous and wider usage of these drugs, reports of 
new toxicities (resulting in their withdrawal from the market), development of patient 
resistance and introduction of better drugs by competitors. Under these conditions, 
standards and analytical procedures for these drugs may not be available in the 
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pharmacopoeias. It becomes necessary, therefore to develop newer analytical 
methods for such drugs. (24) 
 Analytical methods should be used within good manufacturing practice 
(GMP) and good laboratory practice (GLP) environments, and must be developed 
using the protocols set out in the International Conference on Harmonization 
guidelines. (25,26) 
 Method development is a continuous process that progresses in parallel with 
the evolution of the drug product. The goal and purpose of the method should reflect 
the phase of drug development. During early drug development, the methods may 
focus on API behavior. They should be suitable to support preclinical safety 
evaluations, pre-formulation studies, and prototype product stability studies. As drug 
development progresses, the analytical methods are refined and expanded, based on 
increased API and drug product knowledge. The methods should be robust and 
uncomplicated, while still meeting the appropriate regulatory guidelines. Scouting 
experiments are frequently performed during method development to establish the 
performance limits of the method, prior to formal validation experiments. These may 
include forced degradation studies, which are an integral part of development of a 
stability-indicating method. API is typically subjected to degradation by acid, base, 
peroxide, heat, and light. This allows for a determination of the capability of the 
method to separate and quantify degradation products, while providing insight into 
the main mechanisms of degradation. Once a stability-indicating method is in place, 
the formulated drug product can then be subjected to heat and light in order to 
evaluate potential degradation of the API in the presence of formulation excipients.(27) 
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Need for the Development of a New Method 
 Several reasons are available for the development of a new method of 
analysis.(28) 
 There may not be a suitable method for a particular analyte in the specific sample 
matrix. 
 Existing methods may be too erroneous, artefact and/or contamination prone, or 
they may be unreliable (having poor accuracy or precision). 
 Existing methods may be too expensive, time consuming, or energy intensive, or 
they may not be easily automated. 
 Existing methods may not provide adequate sensitivity or analyte selectivity in 
samples of interest. 
 Newer instrumentation and techniques may have evolved that provide 
opportunities for improved methods, including analyte identification or detection 
limits, greater accuracy or precision, or better return on investment. 
 There may be a need for alternative method to confirm, for legal or scientific 
reasons, analytical data originally obtained by existing methods. 
 Method Development Using HPLC 
 In method development, an attempt to select the best chromatographic 
conditions like the best column, the best mobile phase, the detection wavelength etc. 
to be used for routine analysis of any drug is done. For the method development by 
HPLC method some information about the sample is very essential i.e. number of 
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components present in the sample, pKa values of different components, UV-Visible 
Spectra of each analyte, solubility in different solvents, concentration range of each 
component, nature of sample etc. Prior to method development there must be some 
technical information i.e. chromatography method selection according to the sample 
properties, the sample when analyzed with HPLC, the condition where all compounds 
elute in a reasonable time, optimization of HPLC method with regard to analysis 
time, resolution, selectivity and sensitivity. (29) 
 Analyte Standard Characterization 
 All the information about the analyte is gathered regarding the structure, 
physical and chemical properties, toxicity, purity, hygroscopicity, solubility and 
stability. The availability of the 100% pure standard analyte is determined along with 
its storage and disposal information. If multiple components are to be analyzed in a 
sample matrix, the number of components to be analyzed is noted and the availability 
of the standard for each component is checked.(30) 
 Literature Search and Prior Methodology 
 The available literature is searched for all types of information related to the 
analyte. Availability of information regarding the synthesis, physical and chemical 
properties, solubility or relevant analytical methods is determined. Books, periodicals, 
regulatory agency compendia, such as IP, USP/NF, and BP etc. should be referred. 
Chemical Abstracts Service (CAS) automated/ computerized literature searches also 
should be used.  Information pertaining to prior analytical work on the analyte has to 
be determined within the company and compile the available data, results, reports, 
memos and publications.  
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 Choosing a Suitable Method 
 Using the available literature and previous methodology, the methods are 
adapted and modified. Sample preparation and instrument conditions are adopted to 
make use of the latest methods and instrumentation. 
 If no previous methods exist for the analyte in the literature, work from 
analogy to investigate compounds that are similar in structure and properties. Usually 
a compound with analytical method exists that is similar to the analyte of interest.  
1.5    Optimization 
a) Choice of method 
 The most commonly used chromatographic methods are normal phase 
chromatography, reverse phase chromatography, reverse phase ion-pair 
chromatography and ion-exchange chromatography. In the selection of suitable 
chromatographic method for organic compounds, first reversed phase should be tried, 
if not successful, normal phase should be tried, then reverse phase ion-pair 
chromatography should be tried, ion-exchange chromatography at the end.  
b) Choice of Mobile Phase 
 In reversed phase chromatography the selection of mobile phase is very 
important for the analysis of the drug. We can use Acetonitrile frequently as it is 
suitable for the entire UV range, methanol and Isopropanol are not suitable below 
wavelength of 210 nm, acetic acid is suitable above a wavelength of 240 nm, for the 
preparation of buffers, both K2HPO4 and KH2PO4 can be used in entire UV range, 
freshly distilled THF is suitable for HPLC above a wave length of 240 nm, TEA is 
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suitable above 240 nm, ammonium acetate can be used above 215 nm, EDTA can be 
used in entire UV range, sodium phosphate is suitable above 210 nm.  
 The organic phase concentration required for the mobile phase can be 
estimated by gradient elution method. For aqueous sample mixtures, the best way to 
start is with gradient reversed phase chromatography. Gradient can be started with 
10% organic phase in the mobile phase and organic phase concentration (Methanol & 
Acetonitrile) can be increased up to 100% within 20 - 60 min. Separation can then be 
optimized by changing the initial mobile phase composition according to the 
chromatogram obtained from preliminary run. The initial mobile phase composition 
can be estimated on the basis of where the compounds of interest were eluted, at what 
mobile composition. 
 Changing the polarity of the mobile phase can alter the elution of drug 
molecules. The elution strength of a mobile phase depends upon its polarity, the 
stronger the polarity, higher is the elution. Ionic samples (acidic or basic) can be 
separated, if they are present in un-dissociated form. Dissociation of ionic samples 
may be suppressed by proper selection of pH. 
 The pH of the mobile phase has to be selected in such a way that the 
compounds are not ionized. If the retention times are too short, the decrease of the 
organic phase concentration in the mobile phase can be in steps of 5%. If the retention 
times are too long, an increase in 5% steps of the organic phase concentrations is 
needed.  When separating acid or bases, buffered mobile phase is required to maintain 
consistency in retention time and selectivity. Buffered salts reduce peak tailing for 
basic compounds by effectively masking silanol groups and also reduce potential ion-
exchange interactions with a protonated silanol groups. As potassium is a stronger 
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counter ion than sodium, it provides improved results compared to sodium (Na+). 
Potassium phosphate is used for preparation of buffers of various pH. If band tailing 
is observed for basic amphoteric compounds few drops of diluted triethylamine or 
ammonium acetate is added, for acidic or amphoteric compounds, few drops of 
diluted triethylamine or ammonium acetate is tried. For neutral compounds, the 
aqueous eluent used in method development is water, for weak to medium acidic 
compounds, 100 M H3PO4 buffer of pH 2.3, for weak to medium basic or acidic 
compounds in ionized form 100 mM H3PO4 buffer of pH 4.0, 50 mM H3PO4 buffer of 
pH 7.5 are used. Unknown sample should be analyzed first with water, then with an 
acidic and a neutral buffer.  
 During mixing of the solvents in the preparation of mobile phase, the 
difference in partial pressure of the individual solvent at a ratio they are to be 
combined should be considered. The solvent system must be miscible with the 
previously used mobile phase, if not intermediate solvent may be used, the one that is 
miscible with previous mobile phase and new mobile phase. 
c) Choice of Column 
 Columns being the heart of HPLC for optimum separation, Stable, high 
performance column with good selectivity, efficiency is essential requirement for 
rugged and reproducible method. These characteristics are dependent on the columns 
manufacturer’s production of good quality columns and packing materials.  
Column length 
 Longer columns are chosen for increased resolution. 
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 Shorter columns are chosen for shorter analysis time, lower back pressure, fast 
equilibration and less solvent consumption. Column internal diameter 
 Wider diameter columns are chosen for greater sample loading. 
 Narrow columns are chosen for more sensitivity and reduced mobile phase 
consumption. 
Particle shape 
 Columns with spherical particle shapes are preferred when lower back pressure 
column stability and greater efficiency is required. 
 Columns with irregular particle shapes are preferred when large surface area and 
high capacity is required. 
Particle size 
 Columns with small particle size of 3 - 4 µg are preferred for complex mixtures 
with similar components. Combination of a short column  (10 - 50 mm) with 
small particle size is used for fast, high resolution separations. 
 Columns with larger particle size of 5 – 10 µg are preferred for structurally 
different compounds. 
 Columns with large particle of 15 – 20 µg are used for preparative separations. 
Surface area 
 Columns with high surface area packing are selected for more capacity, greater 
resolution and longer retention. 
Chapter 1   Introduction 
Dept. of Pharmaceutical Analysis 33 J.K.K.Nattraja College of Pharmacy 
 Columns with low surface area packing are selected for quicker equilibration 
time. 
Carbon load 
 Columns with high carbon load are chosen for greater column capacities and 
resolution. 
 Columns with low carbon load for faster analysis time. 
End capping 
 Columns with end capped packing are selected to eliminate unpredictable 
secondary interactions with base material 
 Columns with non-end capped packing are selected for selectivity differences for 
polar compounds by controlling secondary interactions.  
a) Choice of Detector 
Detectors are eyes of the liquid chromatography system and measure the 
compounds after their separation on the column. Selected detector should be capable of 
responding to change in concentrations of all the components in the sample with 
adequate sensitivity even to measure trace substances. The detectors must have certain 
characteristics i.e. high sensitivity, higher linear dynamic range, application to most of 
the solutes, does not contribute to band broadening, non-destructive, faster response.  
Further Optimization 
After the selection of a suitable method, mobile phase, column and detector, 
further optimization can be done to obtain a well developed method. 
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For shorter analysis time 
 Change to isocratic method. The suitable mobile phase composition is estimated 
from the gradient run. 
 Use of shorter column, if proper resolution is obtained. 
For better resolution 
 Use of longer column. 
 Use of stationary phase with smaller particles (3 – 4 µg). 
For better selectivity and sensitivity 
 Other stationary phases e.g. phenyl, CN etc. 
 pH control with ion-forming compounds 
 Use of methanol or THF instead of Acetonitrile. 
 Detection at the absorption maximum of the substance 
 All factors which leads to narrower and higher peaks as gradient elution, smaller 
particle, and micro bore columns. (31) 
 
Fig 1.4 Outline of the process involved in method development 
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 1.6    Parameters Affecting Changes in Chromatograph 
The various parameters affecting the changes in chromatographic conditions are 
1. Flow rate 
2. Temperature 
3. pH 
4. Ion pair reagent 
5. Column efficiency 
6. Capacity factor 
7. Resolution  
8. Retention time 
9. Peak asymmetry  
1.   Effect of Flow Rate 
 The efficiency of a HPLC column varies with flow rate. It is sometimes useful 
and readily utilized to increase the resolution. A faster flow rate of the eluent 
minimizes the time required to run a column and thereby minimizes diffusion, 
resulting in a better separation (less band broadening). However, the maximum flow 
rate is limited because a finite time is required for analyte to equilibrate between 
stationary phase and mobile phase. A slower flow rate will decrease the column back 
pressure and a corresponding increase in the run time is observed.(32) 
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Table 1.3 Flow rates for column with different internal diameter. 
Internal diameter of column (mm) Standard flow rate (µl / min) 
4.6 1000 
2.1 200 
1.0 50 
0.30 4 
 
2.    Effect of Temperature 
Elevated temperatures decrease viscosity and increase solubility and diffusivity. 
Retention, peak shape, column efficiency, and total analysis time are affected by 
temperature because both the thermodynamics and kinetics of adsorption processes are 
functions of temperature. Additionally, temperature control results in improved 
reproducibility. In liquid chromatography temperature is used in the optimization of a 
separation.  At higher temperature, peaks will be sharper and elute earlier. System 
pressure is affected by temperature.  The viscosity of the mobile phase decreases with 
increasing temperature. For example if the HPLC system pressure is too high for a given 
solvent system temperature of the column may be raised to 40 0C or even 60 0C. Higher 
temperature will lead to a shorter column lifetime and some columns may not be able to 
tolerate 60 0C. The combination of smaller diameter packing with shorter column lengths 
at elevated temperatures facilitates efficient and fast separations, meeting the high 
throughput performance requirements of the pharmaceutical industry. (33) 
3.  Role of pH 
For some preparations the effect of changing pH is minimal. However for 
acids and bases, a small change in pH is significant. Changing the pH changes the 
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degree of ionization of molecules in solution, affecting polarity of the solution 
thereby changing the retention times in an HPLC separation. In a sample mixture, the 
retention time of the components of the mixture are also changed to different extents. 
Hence it affects the degree of selectivity, where the peaks become further apart or at a 
particular pH they may co-elute and then the peak elution order will change. Selection 
of a proper buffer pH is necessary to reproducibly separate ionizable compounds by 
RP-HPLC. Selection of an improper pH for ionizable analytes leads to asymmetric 
peaks that are broad, tall or split. (34) 
 During the selection of a buffer, pKa of the analyte should be considered. A 
buffer with 2 pH units above or below pKa of the analyte is recommended for a good 
peak shape. From Henderson- Hassel back equation, (35) 
 
 
 It can be determined that 99% of the analyte is in a single form, Good peak 
shape is possible only when an analyte is in a single form. (36) 
4.    Role of Ion-Pair Reagent 
Most of these compounds are ionic or polar; hence the use of reversed phase-
high performance liquid chromatography (RP-HPLC) is somewhat restricted. Initially 
when deciding to select RP-HPLC or RP-HPLC with ion-pairing, the nature of the 
analyte of interest is considered. If the sample is neutral, RP-HPLC is used first; and 
if the sample is ionic, RP-HPLC with ion pairing is used. Thus RP-HPLC and RP-
HPLC with ion pairing are similar except that the latter consists of an ion-pair reagent 
in the mobile phase to improve the selectively of ionic samples. The ionic pair 
pH = pKa + log ([A-]/ [HA]) 
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reagents are large ionic molecules having a charge opposite to the analyte of interest, 
as well as a hydrophobic region to interact with the stationary phase. The counter-ion 
combines with the ions of the eluent, becoming ion pairs in the stationary phase. This 
results in different retention, thus facilitating separation of analytes.  
 The use of an ion-pair reagent is suggested only when separation is not 
adequate with reversed-phase HPLC. This is because using an ion-pair reagent 
introduces additional experimental parameters that need to be controlled, such as 
selection of a suitable ion-pair reagent to use and its concentration. Because of this 
added variable, reversed-phase HPLC should be utilized on any ionic analyte first 
before trying ion-pair reversed–phase HPLC. The approach used in RP-HPLC to 
separate charged analytes is ionic suppression. This technique is based on the pH 
adjustment of the mobile phase to result in a non-ionized analyte. However, this 
requires extensive method development and is only suitable for single compounds or 
simple mixtures where the pKa’s of the analytes lie close together. (37) 
5.    Column Efficiency (N) 
 The efficiency of a chromatographic column is given terms of number of 
theoretical plates (plate number), N 
 
 
Where, tr- retention time measured from the time of injection, w- peak width 
peak width obtained by drawing tangents to the sides of the Gaussian curve at the 
inflection points and extrapolating the tangents to intercept the baseline as in fig 1.6 
 Efficiency of the column is also expressed as height equivalent to theoretical 
plate, (or plate height) HETP (or h) 
  16 	
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Where, L- length of the column, 
 N- Number of theoretical plates. (38) 
 
Fig. 1.5 Pictorial Representation of number of theoretical plates. 
6.    Capacity Factor (k’)  
 It is measure of the position of a sample peak in the chromatogram, being 
specific for a given compound, a parameter which specifies the extent of delay of 
substance to be separated.  
 
Where, tr– retention time of the solute, tm – retention time of the unretained 
compound by the column packing. Fig 1.7 shows capacity factor of a solute. 
 k’ depends at stationary phase, mobile phase, temperature and quality of 
column packing. For good chromatographic performance with isocratic separation, k’ 
value should be in the range of 1-10. If k’ < 1.0, the bands are inadequately separated 
from excessively unretained material, if k’ > 10 separation takes too long and bands 
broadened, if k’ > 30, satisfactory isocratic separation using present column and 
mobile phase is not obtained and gradient elution should be tried.  
   
      
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Fig.1.6 Pictorial representation of capacity factor. 
7. Resolution (Rs) 
The ability of the column to separate two solutes. In a chromatogram it is the 
distance of separation of two peaks.  
 
 
Where,tr1 ,tr2 – retention time of two immediately adjacent peaks, 
 w1, w2 – peak widths of two immediately adjacent peaks as shown in fig 1.8.  
 
Fig.1.7 Pictorial Representation of Resolution. 
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1.    Selectivity factor (α) / Relative Retention  
 This describes the relative position of two adjacent peaks. Ideally, it is 
calculated using the capacity factor because the peaks separation depends on the 
components interaction with the stationary phase. 
 
Where,  
k’a, k’b– capacity factors of peak a and peak b respectively. 
 The value of the separation factor is always greater than unity. The separation 
factor is also identical to the ratio of the corresponding distribution constants. If the 
capacity factor is used, the separation factor should be consistent for a given column, 
mobile phase composition and specified temperature, regardless of the instrument used. 
 
Fig.1.8 Pictorial representation of selectivity factor. 
9.    Peak Asymmetry (As) 
It is also known as tailing factor. The asymmetry factor for a peak can be calculated 
using the following formula. 
 
   
  . 2"  
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Where, W0.05– peak width at 5% height from the base line, 
 f – distance between maximum and leading edge of the peak as in Fig 1.9 
It is also calculated from  
Where, b - distance from the point at peak maxima to the trailing edge,  
a – distance from the leading edge of the peak to the peak maxima (both measured at 
10% height of the baseline) as shown in Fig 2.0.  
 
Fig. 1.9 Pictorial representation of peak asymmetry. 
 Introduction to Method Validation 
 Validation is an integral part of quality assurance; it involves the systematic 
study of systems, facilities and processes aimed at determining whether they perform 
their intended functions adequately and consistently as specified. Validation in itself 
  #$ 
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does not improve processes but confirms that the processes have been properly 
developed and are under control.  
 Method validation is defined as the process of proving (through scientific 
studies) that an analytical method is acceptable for its intended use. To ensure 
compliance with quality and safety standards, the United States, Europe, Japan, and 
other countries have published compendia, or pharmacopeias, that describe official 
test methods for many marketed drug products. For example, analytical methods 
found in United States Pharmacopeia (USP) are legally recognized analytical 
procedures under section 501 (b) of the Federal Food, Drug, and Cosmetic Act. For 
these compendia methods, USP provides regulatory guidance for method validation. 
In addition, validation of analytical methods is covered by the United States Code of 
Federal Regulations (CFR). A great deal of effort has been devoted to the 
harmonization of pharmaceutical regulatory requirements in the United States, 
Europe, and Japan. As part of this initiative, the International Conference on 
Harmonization (ICH) has issued guidelines for analytical method validation. The 
recent FDA methods validation draft guidance documents as well as U.S. both refer 
to ICH guidelines. (39) 
The required validation parameters, also termed analytical performance 
characteristics or analytical figs of merit. Methods should be validated or revalidated 
 Before their introduction and routine use. 
 Whenever the conditions change for which the method has been validated, e.g., 
instrument with different characteristics. 
 Wherever the method is changed and the change is outside the original scope of 
the method.  
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The validation of analytical procedures is directed to the four most common 
types of analytical procedures: Identification tests; Quantitative tests for impurities' 
content; Limit tests for the control of impurities; Quantitative tests of the active 
moiety in samples of drug substance or drug product or other selected component(s) 
in the drug product.  
Method Validation (ICH Guidelines)  
1. Accuracy,  
2. Precision,  
• Repeatability,  
• Intermediate precision. 
3. Specificity / Selectivity,  
4. Limit of Detection,  
5. Limit of Quantitation,  
6. Linearity, 
7. Range,   
8. Robustness,  
9. System Suitability.  
 The validation terminology in ICH guidelines differ from the validation given 
in USP with two exceptions. Ruggedness is not included in ICH guideline and treats 
system suitability as a part of method validation, whereas the USP considers it in a 
separate chapter.  
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Accuracy 
 The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an 
accepted reference value and the value found. Accuracy should be established across 
the specified range of the analytical procedure. 
 Accuracy is measured as the percentage of the analyte recovered by assay, 
spiking samples in a blind study. 
 Accuracy studies for drug substance and drug product are recommended to be 
performed at the 80, 100 and 120% levels of label claim as stated in the Guidelines 
for Submitting Samples and Analytical Data for Methods Validation 
 Accuracy should be assessed using a minimum of 9 determinations over a 
minimum of 3 concentration levels covering the specified range (e.g.3 concentrations 
/3 replicates each of the total analytical procedure). Accuracy should be reported as 
percent recovery by the assay of known added amount of analyte in the sample or as 
the difference between the mean and the accepted true value together with the 
confidence intervals.(40) 
 The acceptance criterion for accuracy is the Relative Standard Deviation 
(RSD) for all the recovery values should not be more than 2.0%. 
 Precision 
 The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions. Precision 
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may be considered at three levels: repeatability, intermediate precision and 
reproducibility. 
 The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of measurements.  
 The relative standard deviation (RSD) for the assay of six sample preparations 
should not be more than 2.0%. 
Specificity 
 Specificity is the ability to assess accurately the analyte in the presence of 
components which may be expected to be present in the sample matrix. Typically 
these might include impurities, degradants, matrix, etc. it is a measure of the degree 
of interference from such other things such as other active ingredients, excipients, 
impurities, and degradation products, ensuring that a peak response is due to a single 
component only.  
 Specificity is divided into two separate categories: identification and assay/ 
impurity tests. For identification purpose, specificity is demonstrated by the ability to 
discriminate between compounds of closely related structures or comparison to a 
known reference standard. For assay/ impurity tests, specificity is demonstrated by 
the resolution of the two closely eluting compounds. These compounds are usually 
the major component or the active ingredient and an impurity. 
 Limit of Detection (LOD) 
 The detection limit of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily quantitated as an 
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exact value. It is a limit test that specifies whether or not an analyte is above or below 
a certain value. 
 It is expressed as a concentration at a specified signal to noise ratio usually a 2 
or 3-to-1 ratio. Two other method can also be used to determine LOD: Visual non-
instrumental methods and a means of calculation: Visual non-instrumental methods 
may include techniques such as thin-layer chromatography (TLC) or titrations. LODs 
may also be calculated based on the standard deviation (SD) of the response and the 
slope (S) of the calibration curve at levels approaching the LOD according to the 
formula:  
  
Where,  
 SD- standard deviation 
 S- Slope 
 The standard deviation of the response can be determined based on the 
standard deviation of the blank, on the residual standard deviation of the regression 
line, or the standard deviation of y-intercepts of regression lines. The method used to 
determine LOD should be documented and supported, and an appropriate number of 
samples should be analyzed at the limit to validate the level.  
Limit of Quantitation (LOQ) 
 The limit of quantitation (LOQ) is defined as the lowest concentration of an 
analyte in a sample that can be determined with acceptable precision and accuracy 
under the stated operational conditions of the method.  
%&  3.3 (&( 	 
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 The ICH has recognized the 10-to-1 signal –to-noise ratio as typical, and as 
for LOD, lists the same two additional options that can be used to determine LOQ: 
visual non-instrumental methods and a means of calculation. The calculation method   
is again based on the standard deviation (SD) of the response and the slope (S) of the 
calibration curve according to the formula, 
 
Where,  
 SD- standard deviation 
 S- Slope 
 Again, the standard deviation of the response can be determined based on the 
standard deviation of the blank, on the residual standard deviation of the regression 
line, or the standard deviation of y-intercepts of regression lines. As with LOD, the 
method used to determine LOQ should be documented and supported, and an 
appropriate number of samples should be analyzed at the limit to validate the level.  
 Linearity and Range 
 Linearity is the ability of the method to elicit test results that are directly 
proportional to analyte concentration within a given range. Linearity is generally 
reported as the variance of the slope of the regression line.  Range is the (inclusive) 
interval between the upper and lower levels of analyte that have been demonstrated to 
be determined with precision, accuracy, and linearity using the method. The range is 
normally expressed in the same units as the test results obtained by the method.  
 A minimum of five concentration levels, along with certain minimum 
specified ranges are to be determined. For assay tests, the minimum specified range is 
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80-120% of the target concentration. For impurity tests, the minimum range is from 
the reporting level of each impurity to 120% of the specification.  
 The relationship between the concentration (in %) of drug in sample and area of 
should be linear in the specified range and the correlation should not be less than 0.9. 
 Robustness   
 Robustness is the capacity of a method to remain unaffected by small 
deliberate variations in method parameters. The robustness of a method is evaluated 
varying method parameters such as percent organic solvent, pH, ionic strength, or 
temperature and determining the effect (if any) on the results of the method.  
 The RSD for the assay of drugs in a sample under deliberately modified 
chromatographic conditions should not be more than 2.0%. 
 System Suitability 
 System suitability tests are an integral part of gas and liquid chromatographic 
methods. They are used to verify that the resolution and reproducibility of the 
chromatographic system are adequate for the analysis to be done. The tests are based 
on the concept that the equipment, electronics, analytical operations and samples to 
be analyzed constitute an integral system that can be evaluated as a whole. (41) 
 System suitability is the checking of a system to ensure system performance 
before or drying the analysis unknowns. Parameters such as plate count, tailing factor, 
resolution and reproducibility (% RSD retention time and area for repetitive. 
injections) are determined and compared against the specifications set for the method. 
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These parameters are measured during the analysis of a system suitability sample that 
is a mixture of main components and expected by-products.   
Table 1.4 Acceptance Limits for System Suitability Test. 
Parameter Limit 
Capacity Factor k’ > 2 
Injection precision RSD < 1% for n ≥ 5 
Resolution Rs  > 2 
Tailing factor As ≤  2 
Theoretical plates N  > 2000 
 
 Definitions and Formulas Used in Method Validation 
 Mean/ Average (xi) 
 The average result (ā) is calculated by summing the individual results and 
dividing the sum by the number (n) of individual values.   
   
 
Where,  x1, x2, x3.. =  Values of individual results 
                     n  = Number of individual results 
 Standard Deviation (SD) 
 It is the root mean square deviation of values from their average. 
 
*+   * - *
 - *. …0  
(&  1∑*  *+0  1  
Chapter 1   Introduction 
Dept. of Pharmaceutical Analysis 51 J.K.K.Nattraja College of Pharmacy 
           Where Σ = Sum of observations 
                     xi = Mean or arithmetic average (Σx / n) 
                     x = Individual observed value 
                  x – xi = Deviation of a value from the mean 
                     n = Number of observations 
Relative Standard Deviation (RSD) 
It is defined as standard deviation expressed as the percentage of mean. 
      
           Where SD = Standard deviation 
                     xi = Mean or arithmetic average (Σx / n 
 Correlation Co-Efficient (R) 
 The correlation coefficient is used to indicate the relationship of two random 
variables. It provides a measure of the strength and direction of the correlation 
varying from -1 to +1. Positive values indicate that the two variables are positively 
correlated, meaning the two variables vary in the same direction. Negative values 
indicate that the two variables are negatively correlated, meaning the two variables 
vary in the contrary direction. Values close to +1 or -1 reveal the two variables are 
highly related. 
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Where n = number of observations 
 x = first value 
 y = second value 
 Σxy = sum of products of first and second value 
 Σx = sum of first values 
 Σy = sum of second values 
 Σx2 =  sum of squares of first value 
 Σy2 = sum of squares of second value 
Linear Regression 
A regression is a statistical analysis assessing the association between two 
variables. It is used to find the relationship between two variables. 
The equation of straight line is     
 
Where  
  B = slope 
 a = intercept  
 
 
Where 
  n = number of observations 
 x = first value 
y = a + bx 
Slope (b) = [n(Σxy) - (Σx) (Σy)]/ [n(Σx2) - (Σx)2) 
Intercept (a) = [(Σy)– b(Σx)]/ n 
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 y = second value 
 Σxy = sum of products of first and second value 
 Σx = sum of first values 
 Σy = sum of second values 
 Σx2 =  sum of squares of first value 
 Σy2 = sum of squares of second value 
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ESOMEPRAZOLE:
Brand Name 
Application 
CAS Number 
Purity   
Molecular Formula 
Molecular Mass 
Description 
Esomeprazole Magnesium is an enantiomer of omeprazole which acts as a 
gastric proton pump inhibitor.    
    
Technical Information
Appearance 
Physical State 
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2. DRUG PROFILE 
 
: Nexium 
: A gastric proton pump inhibitor 
: 217087-09-7 
: ≥98%  
: C17 H19N3O3S  
: 345.417g/mols 
 
Structure                                     
      Fig.2.1 Structure of Esomeprazole 
 
: Powder 
: Solid 
Drug Profile 
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Solubility 
Soluble in methanol, DMSO (143 mg/ml at 25 °C), ethanol (143 mg/ml at     
25 °C), and water (<1 mg/ml at 25 °C). 
Storage : Store at -20° C 
Melting Point : 171-174 °C (dec.) 
Refractive Index : n20D ~1.67 (Predicted) 
Optical Activity : α20/D -139.5º±2.5º, c = 1 in methanol 
IC50 
The PhoP regulon in Salmonella Typhimurium: EC5050 >50 µM;  
the PhoP regulon in Salmonella Typhimurium: IC50 >75 µM 
Indication 
 For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. 
pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use. 
Pharmacodynamics 
 Esomeprazole is a compound that inhibits gastric acid secretion and is 
indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of 
erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer 
recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the 
substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine 
antagonistic properties, but that suppress gastric acid secretion by specific inhibition 
of the H+/K+ATPase at the secretory surface of the gastric parietal cell. By doing so, it 
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inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to 
inhibition of both basal and stimulated acid secretion irrespective of the stimulus. 
Mechanism of Action 
 Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion 
by specific inhibition of the H+/K+ATPase in the gastric parietal cell. By acting 
specifically on the proton pump, Esomeprazole blocks the final step in acid 
production, thus reducing gastric acidity. 
Absorption  : 90% 
Volume of distribution : 16 L [healthy volunteers] 
Protein binding  : 97% 
Half life  : 1-1.5 hours 
Metabolism  
 Mainly hepatic. Esomeprazole is completely metabolized by the cytochrome 
P450 system via CYP2C19 and CYP3A4. Metabolism produces inactive 56ydroxyl 
and desmethyl metabolites, which have no effect on gastric acid secretion. Less than 
1% of the parent drug is excreted in urine. 
Route of Elimination 
 Approximately 80% of the administered dose of esomeprazole is excreted as 
metabolites in urine and the remaining 20% is excreted in feces. 
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LEVOSULPIRIDE 
Synonym : Levosulpiride 
Application : A D2DR inhibitor 
CAS Number : 23672-07-3 
Purity : ≥99% 
Molecular Weight : 341.43 
Molecular Formula : C15H23N3O4S 
Structure     
 
Fig.2.2 Structure of Levosulpiride 
Description    
  (S)-(-)-Sulpiride is a D2DR(D2 dopamine receptor) and D3DR(D3 dopamine 
receptor) inhibitor. 
Technical Information  
Appearance : Crystalline powder 
Physical State : Solid 
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Solubility                  
 Soluble in water (partly), DMF, DMSO (69mg/ml at 25 °C), water (<1 mg/ml 
at 25 °C), and ethanol (10 mM). 
Storage : Store at 4° C 
Melting Point : 183-186 °C (lit.) 
Boiling Point : 529.85 °C (Predicted) 
Density : 1.24 g/cm3 (Predicted) 
Refractive Index : n20D 1.55 (Predicted) 
Optical Activity : α25/D -67.5º±1.5º, c = 2 in DMF 
IC50 
 D3DR: IC50 = 123 nM (human); D2DR: IC50 = 128 nM (human); Dopamine 
D2 receptor: IC50 = 210 nM (rat) 
pK Values : pKa: 9.98 (Predicted), pKb: 8.97 (Predicted) 
Indication      : Sulpiride is indicated for the treatment of schizophrenia. 
Side Effects  
  Genitourinary - Absence of menstrual period, breast enlargement in male,     
spontaneous milk secretion, and changes in libido.  
 Potentially Fatal - Neuroleptic malignant syndrome.  
Storage :  store at room temperature 25oC    
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Mechanism of Action 
 In contrast to most other neuroleptics which block both dopamine D1 and D2 
receptors, sulpiride is more selective and acts primarily as a dopamine D2 antagonist. 
Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, 
histamine, or gamma-aminobutyric acid (GABA) receptors.  
Pharmacodynamics 
 Sulpiride is a substituted benzamide derivative and a selective dopamine D2 
antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives 
include metoclopramide, tiapride, and sultopride. 
Absorption 
 Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral 
bioavailability is only 25 to 35% with marked interindividual differences. 
Half life  :  6 – 8 hour
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LITERATURE REVIEW 
 Deepak Kumar Jain, Nitesh Jain,1 Rita Charde,1 and Nilesh Jain2. et  al (42) 
reported as   A simple, precise, reliable, rapid, sensitive and validated RP-HPLC 
method has been developed to determine esomeprazole magnesium trihydrate 
(ESO) and naproxen (NAP) in synthetic mixture form. Chromatographic 
separation achieved isocratically on Phenomenex, Luna C18 column (5 µm, 
150mm × 4.60mm) and acetonitrile: phosphate buffer (pH 7.0) in the ratio of 
50:50 (v/v) as the mobile phase, at a flow rate of 0.5 ml/min. Detection was 
carried out at 300 nm. The retention times for NAP and ESO was found to be 2.67 
±0.014 and 5.65 ±0.09 min respectively. Parameters such as linearity, precision, 
accuracy, recovery, specificity and ruggedness are studied as reported in the ICH 
guidelines. The method was linear in the concentration range of 50-250 µg/ml for 
NAP and 2-10 µg/ml for ESO with correlation coefficient of 0.999 and 0.998 
respectively. The mean recoveries obtained for NAP and ESO were 100.01% and 
97.76 % respectively and RSD was less than 2. The correlation coefficients for all 
components are close to 1. Developed method was found to be accurate, precise, 
selective and rapid for simultaneous estimation of NAP and ESO. 
 Dipali Patel, Nishitkumar Patel, Reeta Vaishy, Viral Patel, Chiragsinh 
Solanki, and Mitul Patel et al (43) reported as A simple, specific, precise, and 
accurate reversed-phase HPLC method was developed and validated for 
simultaneous estimation of aspirin and esomeprazole magnesium in tablet dosage 
forms. The separation was achieved by HyperChrom ODS-BP C18 column 
(200 mm × 4.6 mm; 5.0 µm) using acetonitrile: methanol: 0.05 M phosphate 
buffer at pH 3 adjusted with orthophosphoric acid (25 : 25 : 50, v/v) as 
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eluent, at a flow rate of 1 mL/min. Detection was carried out at wavelength 
230 nm. The retention times of aspirin and esomeprazole magnesium were 
4.29 min and 6.09 min, respectively. The linearity was established over the 
concentration ranges of 10–70 µg/mL and 10–30 µg/mL with correlation 
coefficients () 0.9986 and 0.9973 for aspirin and esomeprazole magnesium, 
respectively. The mean recoveries were found to be in the ranges of 99.80–
100.57% and 99.70–100.83% for aspirin and esomeprazole magnesium, 
respectively. The proposed method has been validated as per ICH guidelines and 
successfully applied to the estimation of aspirin and esomeprazole magnesium in 
their combined tablet dosage form. 
 Dilip G Maheshwari a and Priti D Trivedi b,* et al (44) reported as A simple, 
accurate, reliable and reproducible HPLC method was developed for the 
simultaneous determination of esomeprazole and domperidone in combined 
dosage forms. The method employed C18 phenomenex column, acetate buffer: 
acetonitrile: methanol (55:35:10) as mobile phase and detection was made at 
290nm. The retention times were found to be 6.76 and 4.42 min for ESO and 
DOMPE respectively. The method was validated as per ICH guidelines. The 
method shows good linearity, accuracy, and precision, limit of detection and limit 
of quantification. The linearity range was found between 4-19 µg/mL for both 
ESO and DOMPE with relative standard deviation of 0.022 and 0.076 
respectively. The value for LOD was found to be 0.3 µg/mL and 0.4 µg/mL and 
LOQ was found to be 1.5 µg/mL and 2.5 µg/mL for ESO and DOMPE 
respectively. The main recovery was found to be 99.81 ± 1.27 and 100.43 ± 1.15 
for ESO and DOMPE respectively. The method was suitable for routine analysis 
of ESO and DOMPE both individually and in combined dosage forms. 
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 ArmAĞAn ÖnAl* And Aysel ÖZtunÇ et al (45) reported as A simple, selective 
and accurate high performance liquid chromatographic (HPLC) method was 
developed and validated for theanalysis of esomeprazole magnesium trihydrate 
(ES) in tablets. Chromatographic separation was achieved isocratically on a 
C18column utilizing a mobile phase of acetonitrile/phosphate buffer (60:40, v/v, 
pH 7) at a flow rate of 1.0 mL/min with UV detection at205 nm. Lansoprazole 
was used as an internal standard (IS). The calibration curve of ES was linear in the 
range of 100~1000 ng/mL(r = 0.9992, n = 4). The RSD values for intra- and inter-
day precision were 0.66~0.86% and 0.84~1.11%, respectively. The proposed 
method was successfully applied to the determination of ES in tablets. The mean 
recovery for ES from the tablets ranged between97.82~98.22%. ES was subjected 
to neutral, acid and alkali hydrolysis as well as oxidation, dry heat treatment and 
photo degradation. Being simple, accurate and selective, the method can be used 
for routine quality control analysis. 
  Ia Hultman, Helene Stenhoff, Mathias Liljeblad et al (46) reported as A LC-
MS/MS method was developed for quantitative determination of esomeprazole, 
and its two main metabolites 5-hydroxyesomeprazole and omeprazole sulphone in 
25 µL human, rat or dog plasma. The analytes and their internal standards were 
extracted from plasma into methyl tert-butyl ether - dichloromethane (3:2, v/v). 
After evaporation and reconstitution of the organic extract the analytes were 
separated on a reversed-phase LC column and measured by atmospheric-pressure 
positive ionisation MS. The linearity range was 20–20,000 nmol/L for 
esomeprazole and omeprazole sulphone, and 20–4000 nmol/L for 5-
hydroxyesomeprazole. The extraction recoveries ranged between 80 and 105%. 
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The intra- and inter-day imprecision were less than 9.5% with accuracy between 
97.7% and 100.1% for all analytes. 
 Patil Shamkant S1,*, Dhabale Pandurang N1, Kuchekar Bhanudas S2 et al 
(47) 
reported as Three simple, precise and economical UV methods have been 
developed for the estimation of Esomeprazole in bulk and pharmaceutical 
formulations. Esomeprazole has the absorbance maxima at 303nm (Method A), 
and in the first order derivative spectra, showed zero crossing at 303nm, with a 
sharp peak at 292nm when n=1 (Method B), Method C applied was Area Under 
Curve (AUC) for analysis of Esomeprazole in the wavelength range of 294310nm. 
Drug followed the Beer's Lamberts range of 5–40 µg/ml for the Method A, B C. 
Results of analysis were validated statistically and by recovery studies and were 
found to be satisfactory. 
 Santaji Uttam Nalwadea, b, et al (48) reported as A novel gradient reversed-phase 
ultra performance liquid chromatographic method has been developed for 
quantitative determination of Esomeprazole magnesium and its seven impurities 
in pharmaceutical dosage forms. Chromatographic separation has been achieved 
on an Acquity BEH C18, 50 mm × 2.1 mm, 1.7 µm with buffered mobile phase 
consisting solvent A (0.04 molar (M) glycine (pH 9.0) buffer) and solvent B 
(mixture of acetonitrile and Milli-Q water in the ratio 90: 10 (v/v); respectively) 
delivered at flow rate of 0.21 mL min−1 and the detection wavelength 305 nm. 
Resolution of Esomeprazole magnesium and all the seven potential impurities has 
been achieved greater than 2.0 for all pairs of compounds. The drug was subjected 
to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic 
degradation. Esomeprazole magnesium was found to degrade significantly in 
oxidative and acid hydrolysis stress conditions and stable in base, hydrolytic and 
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photolytic degradation conditions. The degradation products were well resolved 
from main peak and its impurities, thus proved the stability indicating power of 
the method. The stress samples were assayed against a reference standard and the 
mass balance was found to be close to 99.1%. So this method was also suitable for 
Assay determination of Esomeprazole magnesium in pharmaceutical dosage 
forms. The developed method was validated as per ICH guidelines with respect to 
specificity, linearity, limit of detection, limit of quantification, accuracy, precision 
and robustness. 
 Jin SE1, Ban E, Kim YB, Kim CK. et al (49) reported as A rapid and simple high 
performance liquid chromatography (HPLC) method was developed and validated 
for determination of levosulpiride in human plasma. After extraction with 
ethylacetate/methylene chloride (5:1, v/v), analysis of levosulpiride in plasma 
samples was carried out using a reverse phase C18 column with fluorescence 
detector (maximum excitation at 300 nm and maximum emission at 365 nm) for 
separation and quantification. A mixture of methanol-20 mM phosphate buffer 
(pH 3.5, 16:84, v/v) was used as a mobile phase. The method was specific and 
sensitive with a limit of quantification of 5 ng/ml. This HPLC method was 
validated by examining the precision and accuracy for inter- and intra-day 
analysis in the concentration range of 5-150 ng/ml. The relative standard deviation 
(R.S.D.) in inter- and intra-day validation were 8.16-19.75 and 3.90-11.69%, 
respectively. In stability tests, levosulpiride in human plasma was stable during 
the storage and assay procedure. The method was applied to the bioequivalence 
study of two levosulpiride tablet formulations (25 mg) after a single oral 
administration. 
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  A. Sirisha*, A. Ravi Kumar et al (50) reported as A new simple, precise, accurate 
and selective RP- HPLC method has been developed and validated for estimation 
of Levosulpiride and Rabeprazole in pharmaceutical formulation. The detection 
was carried out at 216nm for both drugs. The retention time for LEVO and RAB 
were found to be 4.918 min. and 5.873 min. respectively. The method was 
validated for precision, recovery, robustness, specificity, and detection and 
quantification limits, in accordance with International Conference on 
Harmonization guidelines. Linearity was observed in the concentration range from 
50% to 150% of nominal concentration of Rabeprazole and Levosulpiride 
Correlation coefficient was 0.999 for both the drugs .The limit of detection and 
quantification of LEVO were 0.021 mg/ml and 0.0731 mg/ml respectively. While 
for RAB it was 0.06 mg/ml and 0.20 mg/ml, respectively. The % recovery was 
found to be within the limits of the acceptance criteria with average recovery of 
101.3% for LEVO and 99.3% for RAB. The % RSD below 2.0 shows the high 
precision of proposed method. 
 Huang MC1, Ho HO, Yeh GC, Ke WT, Lin LC et al (51) reported as An 
improved HPLC method using a silica gel column with fluorescence detection 
(excitation at 300 nm and emission at 365 nm) was developed for the 
determination of sulpiride concentrations in plasma. Analysis of sulpiride in 
plasma samples was simplified by a one-step liquid-liquid extraction after alkaline 
treatment of only 1 ml of plasma. The low limit of quantitation was 20 ng/ml with 
a coefficient of variation of less than 20%. A linear range was found from 20 to 
1500 ng/ml. This HPLC method was validated with the precision for inter-day and 
intra-day runs being 0.36-8.01% and 0.29-5.25%, respectively, and the accuracy 
(standard deviation of mean, SD) for inter-day and intra-day runs being -1.58 to 
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5.02% and -2.14 to 5.21%, respectively. Bioequivalence of the two products was 
evaluated in 12 normal healthy male volunteers in a single-dose, two-period, two-
sequence, two-treatment cross-over study. Sulpiride plasma concentrations were 
analyzed with this validated HPLC method. Results demonstrated that the two 
tablet formulations of sulpiride appear to be bioequivalent. 
 Su-Eon Jin, Eunmi Ban, Yang-Bae Kim, Chong-Kook Kim et al (52) reported 
as A rapid and simple high performance liquid chromatography (HPLC) method 
was developed and validated for determination of levosulpiride in human plasma. 
After extraction with ethylacetate/methylene chloride (5:1, v/v), analysis of 
levosulpiride in plasma samples was carried out using a reverse phase C18 column 
with fluorescence detector (maximum excitation at 300 nm and maximum 
emission at 365 nm) for separation and quantification. A mixture of methanol—20 
mM phosphate buffer (pH 3.5, 16:84, v/v) was used as a mobile phase. The 
method was specific and sensitive with a limit of quantification of 5 ng/ml. This 
HPLC method was validated by examining the precision and accuracy for inter- 
and intra-day analysis in the concentration range of 5–150 ng/ml. The relative 
standard deviation (R.S.D.) in inter- and intra-day validation were 8.16–19.75 and 
3.90–11.69%, respectively. In stability tests, levosulpiride in human plasma was 
stable during the storage and assay procedure. The method was applied to the 
bioequivalence study of two levosulpiride tablet formulations (25 mg) after a 
singleoraladministration
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OBJECTIVE AND PLAN OF STUDY 
 Based on literature review, it is found that a number of studies involving method 
development for estimation of Esomeprazole and Levosulpiride have been carried 
out in formulations/plasma (Human). Thus, a number of analytical methods 
including LC-MS, LC with UV detection in biological specimen, 
spectrophotometry, HPTLC have been developed, but review of literature reveals 
that no method has been developed which can be stability indicating for the 
estimation of Esomeprazole and Levosulpiride in the bulk and capsule dosage 
form by RP- HPLC. 
 No chromatographic methods were reported for estimation of both these drugs             
from their pharmaceutical formulation. Therefore, the objective is to develop       
simple, precise, accurate RP-HPLC method for estimation of Esomeprazole and 
Levosulpiride in its pharmaceutical formulation. 
  Hence the goals of the present work are,  
1. Development and validation of RP-HPLC method for estimation of Esomeprazole 
and Levosulpiride in bulk and pharmaceutical formulation. 
• Selection of solvent 
• Optimization of mobile phase 
• Preparation of calibration curve 
• Validation of the proposed method 
• Application of the proposed method for estimation of drugs in their dosage form.
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MATERIALS AND METHODS 
MATERIALS  
Table 5.1 List of Equipment/Instruments 
S. No. Name Make/ Model 
1 Analytical balance Aicoset 
2 
HPLC instrument 
Series 
Software 
A HPLC system ( WATERS) 
Alliance e2695 
EMPOWER- 2 
3 
Columns 
 
INERTSIL ODS3(250mm,4.6mm,5µ) 
SUNFIRE C18(250mm,4.6mm,5µ) 
HYPERSIL BDS C18 (100,4.6 mm,5µ) 
4 Detector UV-Visible detector 
5 Sonicator SONICA 2200MH 
6 pH meter Metler Toledo 
7 Vacuum filter Model XI 5522050 of Millipore 
 
Table 5.2 List of Chemicals and Reagents 
REAGENT SPECIFICATIONS 
Potassium dihydrogen 
orthophosphate 
(Merck – HPLC grade) 
 
Orthophosphoric acid 
(Merck – HPLC grade) 
 
Ammonium acetate 
( Merck-GR) 
 
Methanol     (Merck hplc grade) 
 
Acetonitrile 
(Merck – HPLC grade) 
Mol. Formula – KH2PO4 
Mol. Weight – 136.09 
 
Mol. Formula – H3PO4 
Mol. Weight – 98 
 
Mol. Formula-CH3COONH4 
Mol. Weight-77.0825 
 
Mol. Formula – CH3OH 
Mol. Weight – 32.04 
 
Mol. Formula – CH3CN 
Mol. Weight – 41.05 
WATER Milli Q grade 
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METHODS 
Preparation of buffer (0.01N KH2Po4) 
Accurately weighed 1.36gm of potassium dihydrogen Ortho phosphate in a 
1000ml of Volumetric flask add about 900ml of milli-Q water  and degas in a 
sonicator and finally make up the volume with water and pH adjusted to 5.4 with dil. 
OPA 
Standard Preparation: 
  Accurately Weighed and transferred 15mg of levosulpiride and 8mg of 
Esomeprazole working Standards into a 10ml clean dry volumetric flask, add 3/4th 
volume of diluent, sonicated for 5 minutes and make up to the final volume with 
diluents. 1ml from the above two stock solutions was taken into a 10ml volumetric 
flask and made up to 10ml.   
Sample Preparation: 
5 tablets were weighed and powdered and transferred into a 50mL volumetric 
flask, 35mL of diluent added and sonicated for 25 min, further the volume made up 
with diluent and filtered. From the filtered solution 0.2 ml was pipeted out into a 10 
ml volumetric flask and made upto 10ml with diluent.   
Linearity: 
 Linearity solutions are prepared such that 0.25ml, 0.5ml, 0.75ml, 1ml, 1.25ml, 
1.5ml from the Stock solutions of Esomeprazole and Levosulpiride are taken in to 6 
different volumetric flasks and diluted to 10ml with diluents to get 20ppm, 40ppm, 
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60ppm, 80ppm, 100ppm, 120ppm of Esomeprazole and 37.5ppm, 75ppm, 112.5ppm 
150ppm, 187.5ppm, 225ppm of Levosulpiride.  
Standard Preparation:  
Accurately Weighed and transferred 15mg of levosulpiride and 8mg of 
Esomeprazole working Standards into a 10ml clean dry volumetric flask, add 3/4th 
volume of diluent, sonicated for 5 minutes and make up to the final volume with 
diluents. 1ml from the above two stock solutions was taken into a 10ml volumetric 
flask and made up to 10ml.   
Sample Preparation: 
5 tablets were weighed and powdered and transferred into a 50mL volumetric 
flask, 35mL of diluent added and sonicated for 25 min, further the volume made up 
with diluent and filtered. From the filtered solution 0.2 ml was pipeted out into a 10 
ml volumetric flask and made upto 10ml with diluent.   
Accuracy 
Standard Preparation:  
Accurately Weighed and transferred 15mg of levosulpiride and 8mg of 
Esomeprazole working Standards into a 10ml clean dry volumetric flask, add 3/4th 
volume of diluent, sonicated for 5 minutes and make up to the final volume with 
diluents. 1ml from the above two stock solutions was taken into a 10ml volumetric 
flask and made up to 10ml.   
Sample preparation 
50%: 5 tablets were weighed and calculate the average weight of each tablet 
then 750mg tablet powder was transferred into a 50mL volumetric flask, 30mL of 
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diluent added and sonicated for 25 min, further the volume made up with diluent and 
filtered. From the filtered solution 0.2ml was pipeted out into a 10 ml volumetric flask 
and made up to 10ml with diluent.   
100%: 5 tablets were weighed and calculate the average weight of each tablet 
then 1500mg tablet powder was transferred into a 50mL volumetric flask, 30mL of 
diluent added and sonicated for 25 min, further the volume made up with diluent and 
filtered. From the filtered solution 0.2ml was pipeted out into a 10 ml volumetric flask 
and made up to 10ml with diluent.   
150%: 5 tablets were weighed and calculate the average weight of each tablet 
then 2250mg tablet powder was transferred into a 50mL volumetric flask, 30mL of 
diluent added and sonicated for 25 min, further the volume made up with diluent and 
filtered. From the filtered solution 0.2ml was pipeted out into a 10 ml volumetric flask 
and made up to 10ml with diluent.   
Method Development 
Many trials were done by changing columns and Mobile phases and were 
reported below. 
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Trial 1 
This trial was run through ods 250 column with mobile phase composition of 
55:45 Buffer and Acetonitrile, Flow rate set at 1ml/min. 
 
Fig 5.1 Trial chromatogram 1 
Observation: resolution is not good 
Trial 2 
This trial was run through ODS 250mm column with mobile phase 
composition of 50:50 A water and Acetonitrile, Flow rate set at 1ml/min. 
 
Fig 5.2 Trial chromatogram 2 
Observation: Esomeprazole eluted in void range. 
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Trial 3 
This trial was run through ODS 250mm column with mobile phase 
composition of 40:60  A water and Acetonitrile, Flow rate set at 1ml/min. 
 
Fig 5.2 Trial chromatogram 3 
Observation: Esomeprazole eluted in void range. 
Optimized Method: Drugs were eluted with good retention time, resolution; all the 
system suitable parameters like Plate count and Tailing factor were within the limits.  
Mobile phase: 
Buffer and Acetonitrile taken in the ratio 32B:68A 
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Chromatographic conditions: 
Flow rate : 1ml/min 
Column  : ODS 150mm x 4.6 mm, 5µ. 
Detector wave length : 290nm 
Column temperature :  30°C 
Injection volume : 10µL 
Run time : 7min 
Diluent    : water:methanol 50:50  
 
Fig 5.4 Optimized chromatogram of Esomeprazole and Levosulpiride 
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RESULTS AND DISCUSSIONS 
1. System suitability 
 All the system suitability parameters are within range and satisfactory as per 
ICH guidelines. 
Table: 6.1 System suitability studies of Esomeprazole and Levosulpiride method 
Property Esomeprazole Levosulpiride 
Retention time (tR) 2.21± 0.3 min 4.01±0.3min 
Theoretical plates (N) 2641 ± 163.48 4414± 163.48 
Tailing factor (T) 1.45 ± 0.117 1.36± 0.117 
 
 
Fig : 6.1 Chromatogram of blank 
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Fig: 6.2 Typical chromatogram of Esomeprazole and Levosulpiride. 
2. Linearity 
 Six Linear concentrations of Esomeprazole(20-120ppm) and 
Levosulpiride (37.5ppm to 225ppm) are prepared and Injected. Regression 
equation of the the Esomeprazole and Levosulpiride are found to be, y = 10568x + 
307.3, y = 11649.x + 120.7 And regression co-efficient was 0.999.
 
Table: 6.2 Calibration data of Esomeprazole and Levosulpiride method 
S. 
No. 
Concentration 
Esomeprazole 
(µg/ml) 
Response 
Concentration 
Levosulpiride 
(µg/ml) 
Response 
1 0 0 0 0 
2 20 219743 37.5 436194 
3 40 420301 75 891483 
4 60 632028 112.5 1323196 
5 80 839036 150 1697713 
6 100 1049902 187.5 2202932 
7 120 1279655 225 2630631 
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Fig: 6.3 Calibration curve of Esomeprazole 
 
Fig: 6.4 Calibration curve of Levosulpiride 
 
Fig: 6.5 Linearity 25% Chromatogram of Esomeprazole and Levosulpiride method. 
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Fig: 6.6 Linearity 50% Chromatogram of Esomeprazole and Levosulpiride method. 
 
Fig: 6.7 Linearity 75% Chromatogram of Esomeprazole and Levosulpiride method. 
 
Fig: 6.8 Linearity 100% Chromatogram of Esomeprazole and Levosulpiride method. 
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Fig: 6.9 Linearity 125% Chromatogram of Esomeprazole and Levosulpiride method. 
 
Fig: 6.10 Linearity 150% Chromatogram of Esomeprazole and Levosulpiride method. 
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3. Precision: 
Intraday precision (Repeatability) 
 Intraday Precision was performed and % RSD for Esomeprazole and 
Levosulpiride were found to be 1.3% and 0.1% respectively. 
Table: 6.3 Repeatability results for Esomeprazole and Levosulpiride . 
Sr. No. Esomeprazole Levosulpiride 
1 814986 1754081 
2 825795 1754437 
3 840851 1758333 
4 819155 1752184 
5 822084 1752359 
6 839797 1754366 
Mean 827111 1754293 
Std. Dev. 10835.5 2217.2 
%RSD 1.3 0.1 
*Average of six determinations 
 
Fig: 6.11 Repeatability Chromatogram of Esomeprazole and Levosulpiride 
method. 
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Inter day precision 
 Inter day precision was performed with 24 hrs time lag and the %RSD 
Obtained for Esomeprazole and Levosulpiride were 1.0% and 0.5%. 
Table 6.4 Inter day precision results for Esomeprazole and Levosulpiride 
Sr. No. Esomeprazole Levosulpiride 
1 834986 1743927 
2 843663 1732187 
3 830708 1728243 
4 848290 1726706 
5 832084 1720428 
6 848665 1739622 
Mean 839732.7 1731852 
Std. Dev. 8135.6 8675.3 
%RSD 1.0 0.5 
 
Fig: 6.12 Inter Day precision Chromatogram of Esomeprazole and Levosulpiride 
method 
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4. Accuracy 
  Three concentrations 50%, 100%, 150%, were injected in a triplicate manner  
and amount Recovered and % Recovery were displayed in Table 6.5. 
Table: 6.5 Accuracy results of Esomeprazole and Levosulpiride 
Sample Amount added (µg/ml) 
Amount 
Recovered 
(µg/ml) 
Recovery (%) % RSD 
 
Esomeprazole 
40 39.04 99.97 0.2 
80 79.82 99.99 0.48 
120 120.99 100.32 0.71 
 
Levosulpiride 
75 75.72 100.250 0.79 
150 150.15 101.58 0.33 
225 225.55 101.48 0.18 
 
 
Fig: 6.13 Accuracy 50% Chromatogram of Esomeprazole and Levosulpiride 
method. 
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Fig: 6.14 Accuracy 100% Chromatogram of Esomeprazole and Levosulpiride 
method. 
 
Fig: 6.15 Accuracy 150% Chromatogram
 of Esomeprazole and Levosulpiride 
method. 
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5. LOD 
 The parameter LOD was determined by analysis of sample with known 
concentration of analyte and by establishing the minimum level at which the analyte 
can be reliably detected. LOD for Esomeprazole and Levosulpiride were found to be 
0.10 and 1.04respectively. 
Fig : 6.16 LOD Chromatogram of Esomeprazole and Levosulpiride method. 
6. LOQ 
 The parameter LOD was determined by analysis of sample with known 
concentration of analyte and by establishing the minimum level at which the analyte 
can be quantified with acceptable accuracy and precision.  LOQ for Esomeprazole 
and Levosulpiride were found to be 0.29 and 1.04 respectively. 
 
Fig : 6.17 LOQ Chromatogram of of Esomeprazole and Levosulpiride method. 
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7. Robustness 
 
  Small deliberate changes in method like Flow rate, mobile phase ratio, and 
temperature are made but there were no recognized change in the result and are within 
range as per ICH Guide lines. 
 
Table 6.6 Robustness data of Esomeprazole and Levosulpiride method. 
S.NO Robustness condition Esomeprazole 
%RSD 
Levosulpiride 
%RSD 
1 Flow minus 0.4 1.0 
2 Flow Plus 0.4 0.4 
3 Mobile phase minus 0.1 0.0 
4 Mobile phase Plus 0.1 0.1 
5 Temperature minus 0.2 0.5 
6 Temperature Plus 0.3 0.5 
 
Fig: 6.18 Flow minus Chromatogram of Esomeprazole and Levosulpiride 
method. 
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Fig: 6.19 Flow plus Chromatogram of Esomeprazole and Levosulpiride method. 
 
Fig: 6.20 Mobile phase minus Chromatogram of Esomeprazole and 
Levosulpiride method. 
 
Fig: 6.21 Mobile phase Plus Chromatogram of Esomeprazole and Levosulpiride 
method. 
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Fig: 6.22 Temperature minus Chromatogram of Esomeprazole and 
Levosulpiride method. 
 
Fig: 6.23 Temperature Plus Chromatogram of Esomeprazole and Levosulpiride 
method. 
Assay 
 Standard preparations are made from the API and Sample Preparations are 
from Formulation. Both sample and standards are injected six homogeneous samples. 
Drug in the formulation was estimated by taking the standard as the reference. The 
Average %Assay was calculated and found to be 100.08% and 101.16% for 
Esomeprazole and Levosulpiride respectively. 
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Table 6.7 Assay of Tablet 
S. No. Esomeprazole 
%Assay 
Levosulpiride 
%Assay 
1 99.51463 101.865 
2 100.5488 101.1793 
3 99.00477 100.9489 
4 101.1002 100.8591 
5 99.16876 100.4924 
6 101.1449 101.6136 
AVG 100.08 101.16 
STDEV 0.97 0.51 
%RSD 0.97 0.50 
 
Fig: 6.24 Assay of Tablet 
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SUMMARY AND CONCLUSION 
7.1 Summary Table 
Parameters Esomeprazole Levosulpiride 
Calibration range (mcg / ml) 20-120ppm 37.5-225ppm 
Optimized wavelength 290nm 290nm 
Retention time 2.2min 4.0min 
Regression equation (Y*) y = 10568.x + 307.3 y = 11649.x + 1207 
Correlation coefficient(r2) 0.999 0.999 
Precision (% RSD*) 0.97 0.50 
% Recovery 100.08% 101.16% 
Limit  of Detection (mcg / ml) 0.10ppm 0.34ppm 
Limit of Quantitation (mcg / ml) 0.29ppm 1.04ppm 
 
Conclusion 
 A simple, Accurate, precise method was developed for the simultaneous 
estimation of the Esomeprazole and Levosulpiride in Tablet dosage form. Retention 
time of Esomeprazole and Levosulpiride were found to be 2.2min and 4.0min. %RSD 
of the Esomeprazole and Levosulpiride were and found to be 0.97 and 0.50 
respectively. %Recover was Obtained as 100.08% and 101.16% for Esomeprazole 
and Levosulpiride respectively. LOD, LOQ values are obtained from regression 
equations of Esomeprazole and Levosulpiride were 0.10ppm, 0.34ppm and 0.29ppm, 
1.04ppm respectively. Regression equation of Esomeprazole is y = 10568x + 307.3, 
and of Levosulpiride is y = 11649.x + 1207. Retention times are decreased and that 
run time was decreased so the method developed was simple and economical that can 
be adopted in regular Quality control test in Industries.    
Chapter 8 Bibliography 
Dept. of Pharmaceutical Analysis 90 J.K.K.Nattraja College of Pharmacy 
BIBLIOGRAPHY 
1. DRUGS & Cosmetics Act, 1940 & Rules, 1945, 2nd edition, Susmit publishers, 
Mumbai, India, 2000.  
2. Methods of Analysis-http://www.pharmatutor.org/pharma-analysis  
3. Skoog; Holler; Crouch; Liquid Chromatography. In Instrumental Analysis, 
Cengage Learning India. New Delhi. 2011; 893.  
4. Chatwal, R. G.; Anand, K. S. High Performance Liquid Chromatography. In 
Instrumental Methods Of Chemical Analysis, 5th ed.; Himalaya Publishers.: 
Mumbai, 2010;  2.570 - 2.629. 
5. Peak shapes - http://www.chem.agilent.com/Library/eseminars/Public/secrets% 
20of%20good%20peak%20shape%20in%20hplc.pdf 
6. Types of  Chromatography- http://www.separationprocesses.com/Adsorption/AD_ 
Chp05a.htm 
7. Adsorption Chromatography- http://cemca.org/andcollege/andcwebsite/subject01 
/CHEtext.pdf. 
8. Adsorption Chromatography-  http://www.separationprocesses.com/Adsorption 
/AD_Chp05a.htm. 
9. Partition Chromatography - http://media.rsc.org/Modern%20chemical%20 
techniques/MCT5%20Chromatography.pdf 
Chapter 8 Bibliography 
Dept. of Pharmaceutical Analysis 91 J.K.K.Nattraja College of Pharmacy 
10. Ion Exchange Chromatography - http://www.gelifesciences.com/webapp/ 
wcs/stores/servlet/catalog/en/GELifeSciences-IN/products/ion-exchange-
chromatography-iex/ 
11. Ion Exchange Chromatography-http://wolfson.huji.ac.il/purification/PDF/ 
IonExchange/AMERSHAM_iIEXandChromatofocManual.pdf 
12. Size exclusion chromatography- http://www.rpi.edu/dept/chemeng/Biotech 
Environ/CHROMO/be_types.htm 
13. Chiral phase chromatography- http://scholar.lib.vt.edu/theses/available/etd 
32298223814/unrestricted/ch_02.pdf 
14. Types of elution- http://chemwiki.ucdavis.edu/@api/deki/pages/402/pdf 
15. Types of elution- http://hplc.chem.shu.edu/NEW/HPLC_Book/Rev. Phase/rp_ 
grad.htmL 
16. Diagram of HPLC - http://hiq.lindegas.com/international/web/lg/spg/like 
35lgspg.nsf/docbyalias/image_hplc 
17. Solvent Delivery System - http://www.monzirpal.net/Instrumental%20Analysis/ 
Lectures/Lectures%2021-/L39.pdf 
18. Injection valves - http://www.dolomitemicrofluidics.com/webshop/ 
flowaccessoriesinjection-valves-c-17_18/sample-injection-valve-p-783 
19. Injection valves -http://weather.nmsu.edu/Teaching_Material/SOIL698/ Student_ 
Material/Hplchp1090/Hplcinj.Html 
Chapter 8 Bibliography 
Dept. of Pharmaceutical Analysis 92 J.K.K.Nattraja College of Pharmacy 
20. Flow path of a Manual Injector - http://polymer.ustc.edu.cn/xwxx_20/xw/201109/ 
P020110906263097048536.pdf 
21. Braithwaite, A.; Smith, F. J. Liquid Phase Chromatography on Columns. In 
Chromatographic methods, 5th ed.; Kluwer Academic Publishers: Netherlands, 
1999; 129. 
22. Detectors – http://lipidlibrary.aocs.org/topics/detect92/file.pdf 
23. Detectors – http://www.shodex.net/index.php?seitenid=1&applic=1485 
24. Method development - http://www.pharmainfo.net/reviews/introduction analytical 
method development pharmacutical-formulations 
25. International Conference on Harmonization, "Q2A: Text on Validation of 
Analytical Procedures," Federal Register. 1995, 60, 11260–11262. 
26.  International Conference on Harmonization, "Q2B: Validation of Analytical 
Procedures: Methodology; Availability," Federal Register. 1997, 62, 27463–
27467. 
27. Michael Swartz, E.; Ira Krull, S, Analytical Method development. In Analytical 
Method Development and Validation, 1st ed.; Marcel Dekker, Inc: New York, 
2009; 17-80. 
28. Particle Sciences Drug Development Services. Analytic Method Development and 
Validation. Technical Brief. 2009, 5, 1-2. 
29. Methods of Analysis-http://www.pharmatutor.org/pharma-analysis 
Chapter 8 Bibliography 
Dept. of Pharmaceutical Analysis 93 J.K.K.Nattraja College of Pharmacy 
30. Manoj, K. S.; Pramod, K. S.; Sambhu, C. M.; Preet, K. K.; Nitin, K.;Rupesh, D. A 
perspective review on method development and validation by HPLC. International 
Journal of Pharmaceutical Sciences.2011, 4, 1387-1413. 
31. Radhika, R.; Alfred, D. G. Guidance for Industry- Analytical Procedures and 
Methods V1alidation. Federal Register, 2000, 2396, 1-32. 
32. Effect of flow rate - http://www.ionsource.com/tutorial/chromatography/ 
rphplc.htm 
33. Brian, L. H.; Thomas, E. B. The Influence of Column Temperature on HPLC 
Chiral Separation on Macrocyclic Glycopeptide CSPs. Advanced Separation 
Technologies Inc. (Astec). New Jersey, USA. 
34. Effect of pH-http://www.laserchrom.co.uk/LaserchromHPLC-pHBufferGuide.htm 
35. Effect of pH - Technical tips-selecting buffer ph in reverse phase HPLC 
36. Effect of pH- http://www.sigmaaldrich.com/content/dam/sigmaaldrich/docs 
/Fluka/General_InformatIon/analytixnotes_lpc_lowres.pdf 
37. Effect of ion-pair reagent- http://www.standardbase.com/tech/HPLC%20 
validation%20PE.pdf 
38. Types of HPLC- http://www.chem.agilent.com/Library/primers/Public/ 
59896639EN.pdf 
39. Jay, B.; Kevin, J.; Pierre, B.  Understanding and Implementing Efficient 
Analytical Methods Development and Validation. Pharmaceutical Technology 
Analytical Chemistry & Testing. 2003, 5, 6 - 13. 
Chapter 8 Bibliography 
Dept. of Pharmaceutical Analysis 94 J.K.K.Nattraja College of Pharmacy 
40. Ghulam, A. S.  HPLC Method Development and Validation for Pharmaceutical Analysis. 
Pharmaceutical Technology Europe. 2004, 7, 55 -63. 
41. Ludwig, H. Validation of Analytical Methods. Agilent technologies. 2007, 1- 65. 
42. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. 
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin 
Pharmacol. 2001;40:411–26. [PubMed] 
43. Nanda R, Gaikwad J and Prakash A. Simultaneous spectrophotometric estimation 
of esomeprazole and ornidazole in tablet dosage form. Int.J PharmTech Res. 
2009;1(3):488-91 
44. Zahra talebpour et al., developed as  Determination of Esomeprazole by a 
Validated Stability-Indicating HPLC Method and Identification of its Related 
Substances by LC-MS/MS Studies from Sci Pharm. Jun 2013; 81(2): 493–503. 
45. Hanamanth J Kallur et al., developed as Simultaneous estimation of Etodolac and 
Levosulpiride in bulk drug dosage form by RP-HPLC in IJAPA VOL 3 NO 3 
(2013)>KALLUR. 
46. T.A. Phazna Devi1 et al., devolped as Method development and validation of 
levosulpiride drug by RP-HPLC in JMedAlliedSci2013 ; 3(1):08-14. 
47. M. Levent ALTUN et al., developed HPLC Method for the Analysis of 
Levosulpiride, Caffeine and Dipyrone in Turk J Chem 26 (2002) , 521 – 528.  
  
Chapter 8 Bibliography 
Dept. of Pharmaceutical Analysis 95 J.K.K.Nattraja College of Pharmacy 
48. K. V. Lalitha, et al., reported as RP-HPLC Method Development and Validation 
for the Simultaneous Estimation of Levosulpiride and Flupiritine Maleate in 
Pharmaceutical Dosage in Journal of Scientific and Innovative Research 2013; 2 
(3): 634-641. 
49. Sadana Gangishetty et al ., RP-HPLC Method Development and Validation for 
Simultaneous Estimation of Clarithromycin and Levosulpiride in ISRN Analytical 
ChemistryVolume 2013 (2013), Article ID 948547, 5 pages. 
50. S. S. Narwade et al ., developed as Qualitative and Quantitative Analysis of 
Levosulpiride in Different Drug Samples by HPLC Technique in  IOSR Journal of 
Applied Chemistry (IOSR-JAC) e-ISSN: 2278-5736.Volume 7, Issue 8 Ver. I. 
(Aug. 2014), PP 46-49. 
51. USP 31/NF 26, United States Pharmacopoeia, 31st rev. and the National 
Formulary, 26 ed. United States Pharamcopoeial Convention, Rockville, 2008. 
52. Santhi N, Rajendran S, Kumar N, Solomon S, Narayanan S. Simultaneous 
estimation of esomeprazole and ofloxacin in bulk and tablet dosage form. Asian J. 
Pharm. Ana. 2011;1(3):50-2. 
 
